Recombinant antibodies have made a tremendous impact
on biomedical research and are increasingly being
used as clinical diagnostic and therapeutic
reagents. The discovery of the tumor markers, opened
a new era in the development of antibody-targeted
cancer therapy. This book evaluates the potential of
recombinant derivatives of an anti-MUCI and an anti-
ErbB2 Mabs to serve as tools for breast cancer
detection and therapy. To explore the potential of
Mabs in antibody-targeted cancer therapy, a novel
IgG-toxin immunoconjugate is described. This work
provides evidences that bivalent...